A groundbreaking mRNA vaccine (mRNA-1647) demonstrates superior efficacy against cytomegalovirus infection in phase 3 clinical trials, offering new hope for preventing CMV transmission.
Moderna reported $3.2 billion in total revenue for fiscal year 2024, with a net loss of $3.6 billion as the company transitions from pandemic to seasonal COVID-19 vaccine market.